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Viral suppression is the ultimate goal of HIV treatment. 
HIV treatment has dramatically improved the health, 
quality of life, and life expectancy of people living with HIV. 
Additionally, people living with HIV who take HIV medicine as 
prescribed and get and keep an undetectable viral load have 
effectively no risk of transmitting HIV to their HIV-negative 
sexual partners.
By ensuring that everyone with HIV is aware of their infection, 
receives the treatment they need, and achieves sustained viral 
suppression, we can sharply reduce new infections and thereby 
reduce new HIV diagnoses in the United States. 
The “Selected National HIV Prevention and Care Outcomes” are 
select indicators that are used to monitor progress toward U.S. 
national goals outlined in the National HIV/AIDS Strategy, 2020 
(NHAS 2020). Because the bars use different denominators, the 
data are presented as separate bar charts. 
National HIV Indicators
There are 13 indicators to track 
progress towards NHAS 2020 goals. 
Several specific indicators 
related to HIV diagnosis, effective 
care and treatment include:
Knowledge of HIV serostatus 
(i.e., diagnosed HIV infection)
  Linkage to HIV medical care
  Retention in HIV medical care 
  Viral Suppression
Diagnosed Infection among Persons Aged > 13 
Years Living with Diagnosed or Undiagnosed HIV 
Infection, by Sex 2016 • United States
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Note: Estimates derived from a CD4 depletion model using 
HIV surveillance data.
Linkage to HIV Medical Care within 1 Month after HIV Diagnosis 
during 2017 among Persons Aged > 13 Years, by Sex • 41 States 
and the District of Columbia
Note: Linkage to HIV medical care was defined as having 
a CD4 or VL test ≤ 1 month after HIV diagnosis
Note: Receipt of medical care was defined as ≥1 test (CD4 or VL) in 2016. Retained in continuous medical care was defined as ≥ 2 tests 
(CD4 or VL) ≥ 3 months apart in 2016. Viral suppression was defined as < 200 copies/mL on the most recent test in 2016.
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The data source for the “Select HIV Care 
Outcomes” is the National HIV Surveillance 
System (NHSS). NHSS provides a range of 
information on people who received a diagnosis 
in a particular year, live with diagnosed HIV or 
have died with HIV. The data are reported to 
CDC by state and local health departments.  
The most recent data on linkage to care, 
retention in care, and viral suppression are  
from 42 jurisdictions (41 states and D.C.) that 
have complete lab reporting. These jurisdictions 
represent 89% of persons living with diagnosed 
HIV in the United States. Persons are assigned 
to the 42 jurisdictions based on residence at 
diagnosis for linkage to care and on the most 
recent known address for retention and viral 
suppression. For additional details on how  
these outcomes are calculated, see Table 1.
Diagnosed HIV infection in the United States 
is measured as the percentage of persons 
living with diagnosed HIV among the estimated 
number of persons living with diagnosed or 
undiagnosed HIV infection at year-end 2016. 
The denominator is all persons living with HIV 
(includes diagnosed or undiagnosed HIV and  
is estimated through modeling). 
 
Importance Of Complete 
Laboratory Reporting
Measuring the components of the continuum 
of care and progress toward the goals of the 
National HIV/AIDS Strategy, 2020, relies on 
laboratory reporting of HIV–related tests 
to the local and national HIV surveillance 
systems. The CDC recommends reporting of 
all HIV–related test results, including CD4+T-
lymphocyte (CD4) results and all viral load test 
results. This comprehensive laboratory reporting 
recommendation is in alignment with the Council 
of State and Territorial Epidemiologists’ (CSTE) 
position (ID: 2001-ID-03). Laboratory data, 
including CD4 and viral load test results, are 
an essential component of the National HIV 
Surveillance System (NHSS) as they can be 
used to identify cases, classify stage of disease 
at diagnosis, and monitor disease progression. 
These data can be used to evaluate HIV testing 
and prevention efforts, determine entry into 
care, retention in care, and monitor viral load 
suppression.
How Selected National HIV Care Outcomes are  
used to Monitor Progress and Identify Needs
JULY 2019
The outcomes are defined using national 
indicator definitions. At the national level, these 
data are used to inform decisions about how to 
best prioritize and target available resources 
and to monitor progress toward meeting national 
goals. Because NHSS data are available at the 
state and local levels, the national level indicators 
were defined in a way that allows states to use 
their data to track progress over time and identify 
where improvements are needed.
Ways of presenting HIV care outcomes will continue 
to evolve over time as better and more complete 
data become available. For more information on 
data used to monitor outcomes, refer to “Monitoring 
Selected National HIV Prevention and Care 
Objectives by Using HIV Surveillance data, United 
States and 6 Dependent Areas – 2017. https://www.
cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-
surveillance-supplemental-report-vol-24-3.pdf 
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Table 1. Selected National HIV Prevention and Care Outcomes 
Continuum Step
Diagnosed Measures the percentage of the total number of people living with HIV whose infection  
has been diagnosed. 
The denominator is HIV prevalence, which is the total number of people living with HIV 
(includes both those with diagnosed infection and those with undiagnosed infection). 
HIV prevalence is estimated through statistical modeling¹ using National HIV Surveillance 
System (NHSS) data from all U.S. states and the District of Columbia (DC).  
Receipt of Care NHSS data from states and DC with complete reporting of CD4 and viral load test  
results are used to estimate “receipt of care” and “retained in care.” 
Receipt of care is measured as the percentage of persons with diagnosed HIV who  
had at least one CD4 or viral load test.
The denominator for the prevalence-based continuum is all persons living with HIV  
(HIV prevalence). The denominator for the diagnosis-based continuum is all persons 
living with diagnosed HIV (diagnosed prevalence*).
Retained in Care NHSS data from states and DC with complete reporting of CD4 and viral load test results 
are used to estimate “receipt of care” and “retained in care.” 
Retained in care is measured as the percentage of persons with diagnosed HIV who  
had two or more CD4 or viral load tests performed at least three months apart.  
The denominator for the prevalence-based continuum is all persons living with HIV  
(HIV prevalence). The denominator for the diagnosis-based continuum is all persons 
living with diagnosed HIV (diagnosed prevalence*).
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Viral Suppression NHSS data from states and DC with complete reporting of CD4 and viral load test results 
are used to estimate “viral suppression.”
Viral suppression is measured as a viral load test result of <200 copies/mL at the most 
recent viral load test during measurement year.
The denominator for the prevalence-based continuum is all persons living with HIV (HIV 
prevalence). The denominator for the diagnosis-based continuum is all persons living 
with diagnosed HIV (diagnosed prevalence*).
Linked to Care NHSS data from states and DC with complete reporting of CD4 and viral load test 
results are used to determine “linked to care.”
Linked to care measures the percentage of people receiving a diagnosis of HIV in 
a given calendar year who had one or more documented CD4 or viral load tests  
within 30 days (1 month) of diagnosis. 
Because this measure is limited to people with HIV diagnosed only in a single year, 
it cannot be directly compared to other steps in the continuum. This means that the 
denominator for linkage to care is different from the denominators used to calculate 
the other steps in the continuum. It is also important to note that an individual who 
enters care more than 30 days after diagnosis may still be included in subsequent 
steps of the continuum, but would not be counted as “linked to care.”
*Diagnosed prevalence is defined as the number of persons with HIV diagnosed through the end of 1 year and are living through the end of the  
next year (e.g. diagnosed prevalence for 2016 is defined as persons receiving a diagnosis of HIV by end of 2015 and living through the end of 2016).
¹ Song R, Hall HI, Green T, et al. Using CD4 Data to Estimate HIV Incidence, Prevalence, and Percent of Undiagnosed Infections in the United States. 
2017. J Acquir Immune Defic Syndr; 74: 3-9.
